View all companies
Recommendation
Start reading our world-class research today.
Already have an account?
Log in
13 articles for Tenth of Ramadan Pharmaceuticals and Diagnostic Reagents Co
Rameda Pharmaceuticals: Solid revenues, healthy margins, interest income, and FX gain drive performance
Retail pharma has partially recovered in 2021, which confirms the sustainability of the gradual sequential recovery expected in 2022. Such YoY growth is higher than 2020 retail pharma market growth (+4% YoY growth) but is still below 2019 double-digi...
Mariam Wael @ Al Ahly Pharos Securities Brokerage 12 May 2022
Rameda Pharmaceuticals: New launches drive revenues; Bottom-line grows on enhanced operating leverage
Retail pharma has partially recovered in 2021, which confirms the sustainability of the gradual sequential recovery expected in 2022. During 2021, RMDA’s private sales recorded EGP829 million, an increase of +25.6% YoY. RMDA’s ASP for the retail mark...
Mariam Wael @ Al Ahly Pharos Securities Brokerage 24 February 2022
Flash Report /
Egypt
Rameda: Meet the management webinar – key takeaways
The retail pharma market continued to sequentially recover during 11M21, which confirms the sustainability of the gradual sequential recovery expected in 4Q21 and accordingly in 2022 and thereafter. Retail pharma market volumes recorded a decline of ...
Mariam Wael @ Al Ahly Pharos Securities Brokerage 19 January 2022
Egypt Pharma 2022: Well positioned for recovery, supported by favorable dynamics
Egypt is the MEA region’s largest producer and second largest consumer of pharmaceuticals, growing at a CAGR of 17% over 2013a-2020a, surpassing the region’s CAGR of 8%. Despite pressure during the past couple of years because of the pandemic, we for...
Mariam Wael @ Al Ahly Pharos Securities Brokerage 25 November 2021
Rameda Pharmaceuticals: Private sales drive revenue growth, solid bottom line growth
The retail pharma market continued to sequentially recover during 9M21, which confirms the sustainability of the gradual sequential recovery expected in 4Q21. During 3Q21, RMDA’s private sales recorded EGP240 million (+27.2% YoY, +35.9% QoQ), where v...
Mariam Wael @ Al Ahly Pharos Securities Brokerage 16 November 2021
Rameda Pharmaceuticals: Private sales recovery supports performance despite UMPA challenges
According to IQVIA, retail pharma sales recorded EGP39.86 billion during 1H21, showing a modest growth of 7% YoY, according to the latest available data. During 2Q21, RMDA’s private sales recorded EGP177 million (+39.5% YoY, +4.1% QoQ), where volumes...
Mariam Wael @ Al Ahly Pharos Securities Brokerage 9 August 2021
Details
Egypt
Africa
Health Care Equipment & Services
About
Tenth of Ramadan Pharmaceuticals and Diagnostic Reagents Co operates as pharmaceutical company. The Company manufactures vitamins, anti-infective, and other related drugs and medicines for various types of diseases. Tenth of Ramadan Pharmaceuticals and Diagnostic Reagents serves customers in Egypt.
